A Report on Myocarditis Adverse Events in the U.S. (VAERS) in Association with COVID-19 Injectable Biological Products

Following the global rollout and administration of the Pfizer Inc./BioNTech BNT162b2 and Moderna mRNA-1273 vaccines on December 17, 2020, in the United States, and of the Janssen Ad26.COV2.S product on April 1st, 2021, in an unprecedented manner, hundreds of thousands of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS). We used VAERS data to examine cardiac AEs, primarily myocarditis, reported following injection of the first or second dose of the COVID-19 injectable products.

[link to www.sciencedirect.com (secure)]

Last Edited by me777 on 10/02/2021 08:10 AM